^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral replication inhibitor

    Related drugs:
    3d
    Study of Obeldesivir as Postexposure Prophylaxis for Marburg Virus Disease (clinicaltrials.gov)
    P2, N=400, Not yet recruiting, Gilead Sciences
    New P2 trial
    5d
    The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data (ChiCTR2400089338)
    P=N/A, N=200, Not yet recruiting, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and
    New trial
    8d
    Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    New P1 trial
    11d
    A Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of Multiple Doses of ALG-000184. (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Aligos Therapeutics
    New P1 trial
    |
    itraconazole
    14d
    A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Peking University Third Hospital
    New trial
    14d
    Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Sichuan Provincial People's Hospital
    New trial • Real-world evidence • Real-world
    14d
    MOVe-NOW: A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (clinicaltrials.gov)
    P3, N=3082, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial
    17d
    A Study of RBD1016 in CHB Participants (clinicaltrials.gov)
    P2, N=48, Recruiting, Suzhou Ribo Life Science Co. Ltd. | N=104 --> 48
    Enrollment change
    17d
    A Study of JNJ-64281802 for the Prevention of Dengue Infection (clinicaltrials.gov)
    P2, N=1256, Terminated, Janssen Research & Development, LLC | N=1850 --> 1256 | Trial completion date: May 2025 --> Jun 2024 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Jun 2024; The study was stopped due to portfolio reprioritization. This decision is not based on any safety concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    18d
    A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants (clinicaltrials.gov)
    P2, N=0, Withdrawn, Janssen Research & Development, LLC | N=54 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    23d
    Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, GemVax & Kael | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    LucaVax (tertomotide)
    23d
    GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov)
    P2, N=78, Completed, GemVax & Kael | Recruiting --> Completed | Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Dec 2023 --> Oct 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    LucaVax (tertomotide)
    25d
    Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov)
    P2, N=240, Recruiting, Gilead Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    29d
    Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension (clinicaltrials.gov)
    P1, N=40, Recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    New P1 trial
    1m
    Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects (clinicaltrials.gov)
    P1, N=56, Recruiting, GemVax & Kael | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LucaVax (tertomotide)
    1m
    A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (clinicaltrials.gov)
    P2, N=60, Recruiting, Vigonvita Life Sciences | Trial primary completion date: Sep 2024 --> Jan 2025
    Trial primary completion date
    1m
    A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov)
    P2/3, N=16, Terminated, Pfizer | Active, not recruiting --> Terminated; Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study.
    Trial termination
    1m
    A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV (clinicaltrials.gov)
    P1, N=10, Terminated, Pfizer | N=108 --> 10 | Trial completion date: Apr 2025 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Apr 2025 --> Sep 2024; Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    1m
    Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, GemVax & Kael
    New P1 trial
    |
    LucaVax (tertomotide)
    2ms
    A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011) (clinicaltrials.gov)
    P1, N=64, Completed, Merck Sharp & Dohme LLC
    New P1 trial
    2ms
    PROLIFIC: imPROving Quality of LIFe In the Long COVID Patient (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Karolinska Institutet | Recruiting --> Active, not recruiting | N=400 --> 180 | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Jan 2024 --> Nov 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • HEOR
    |
    ritonavir
    2ms
    COVID: Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, National Taiwan University Hospital
    New trial
    2ms
    A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Antiva Biosciences | N=29 --> 110 | Trial completion date: May 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Jun 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A expression
    2ms
    A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients (clinicaltrials.gov)
    P2, N=135, Completed, Oneness Biotech Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    2ms
    Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma. (PubMed, Biomaterials)
    As expected, application of ERV improved the efficacy of anti-PD1. Overall, our results approved that ERV enhances the efficacy of anti-PD1 immunotherapy in melanoma by promoting the polarization of M1 macrophages, which provided novel therapeutic strategy for improving the effectiveness of melanoma anti-PD1 immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CCL5 (Chemokine (C-C motif) ligand 5) • MAPK8 (Mitogen-activated protein kinase 8)
    2ms
    A study on the pharmacokinetic characteristics and penetration of Eravacycline in the pulmonary bronchial fluid of adult patients with hospital-acquired pneumonia or ventilator-associated pneumonia (ChiCTR2400087137)
    P4, N=16, Not yet recruiting, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New P4 trial
    2ms
    A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov)
    P2/3, N=6, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=2715 --> 6 | Trial completion date: Mar 2026 --> Sep 2024 | Trial primary completion date: Mar 2026 --> Sep 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    2ms
    Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Gilead Sciences
    New P2 trial
    3ms
    Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza (clinicaltrials.gov)
    P3, N=748, Not yet recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    New P3 trial
    3ms
    Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications (clinicaltrials.gov)
    P3, N=328, Not yet recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    New P3 trial
    3ms
    Study Investigating the Safety and Immunogenicity of AB-729 and VTP 300 in Virologically Suppressed CHB Participants (ACTRN12622000317796)
    P2, N=62, Active, not recruiting, Arbutus Biopharma | Recruiting --> Active, not recruiting | N=40 --> 62
    Enrollment closed • Enrollment change
    |
    IFNG (Interferon, gamma)
    |
    Opdivo (nivolumab)
    3ms
    Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection (clinicaltrials.gov)
    P2, N=0, Withdrawn, Arbutus Biopharma Corporation | N=30 --> 0 | Trial completion date: Jul 2027 --> Aug 2024 | Recruiting --> Withdrawn | Trial primary completion date: Feb 2027 --> Aug 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy
    |
    Imfinzi (durvalumab)
    3ms
    Utilizing Plasma-Based Next-Generation Sequencing to Expedite the Diagnostic Process in Suspected Lung Cancer: A Case Report. (PubMed, Int J Mol Sci)
    The patient was Coronavirus disease 2019-positive and was treated with molnupiravir on Day 6...The patient was started on targeted therapy (afatinib) on Day 9...Plasma-based NGS offers a rapid and efficient means of mutation detection in NSCLC, streamlining treatment initiation and potentially improving the negative emotions of patients. Its utility, particularly in regions with a high prevalence of specific mutations, such as EGFR alterations in East Asian populations, highlights its relevance in guiding personalized therapy decisions.
    Journal • Next-generation sequencing • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    Gilotrif (afatinib)
    3ms
    A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults. (clinicaltrials.gov)
    P1, N=40, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    3ms
    Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Antiva Biosciences | Trial completion date: Aug 2025 --> Feb 2026
    Trial completion date
    4ms
    The Cell-Penetrating Peptide GV1001 Enhances Bone Formation via Pin1-Mediated Augmentation of Runx2 and Osterix Stability. (PubMed, Biomolecules)
    GV1001 demonstrated protective effects against bone loss in OVX mice by upregulating osteogenic differentiation via the Pin1-mediated protein stabilization of Runx2 and Osterix. GV1001 could be a potential candidate with anabolic effects for the prevention and treatment of osteoporosis.
    Journal
    |
    PIN1 (Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1) • RUNX2 (RUNX Family Transcription Factor 2)
    |
    LucaVax (tertomotide)
    4ms
    i-LIVER: Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B (clinicaltrials.gov)
    P2, N=10, Recruiting, University of Maryland, Baltimore | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19 (clinicaltrials.gov)
    P=N/A, N=3000, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease (clinicaltrials.gov)
    P3, N=160, Recruiting, Pfizer | Phase classification: P2/3 --> P3
    Phase classification
    4ms
    A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function (clinicaltrials.gov)
    P1, N=16, Completed, Pfizer | Recruiting --> Completed | N=24 --> 16
    Trial completion • Enrollment change
    4ms
    A Multi-Center Single-Blind, Randomized, Controlled Trial Evaluating the SARS-CoV-2 Rebound rate after full-course treatment of JT001 (VV116) Compared to Paxlovid for the Early Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19) (ChiCTR2200066811)
    P3, N=478, Completed, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine | Not yet recruiting --> Completed
    Trial completion
    4ms
    Novel immunomodulatory properties of adenosine analogs promote their antiviral activity against SARS-CoV-2. (PubMed, EMBO Rep)
    In the case of remdesivir, we here show that these properties are due to its metabolite, GS-441524, acting as an Adenosine A2A Receptor antagonist. Our findings support a new rationale for the design of next-generation antiviral agents with dual - immunomodulatory and intrinsic - antiviral properties. These compounds could represent game-changing therapies to control emerging viral diseases and future pandemics.
    Journal • Immunomodulating
    |
    ADORA2A (Adenosine A2a Receptor)